5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia

The ponatinib PACE trial (NCT01207440) enrolled patients with CML or Ph+ ALL resistant/intolerant to dasatinib or nilotinib, or with T315I. Here, we report 5-year outcomes in CP-CML patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge E. Cortes, Hagop M. Kantarjian, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Stephanie Lustg Source Type: research